LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Octobre 2024 - 12:25AM
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today
announced that a majority of the independent members of LENSAR’s
board of directors granted two newly-hired non-executive employees
stock options to purchase an aggregate of 875 shares of the
Company’s common stock. The options were granted as of October
1, 2024, as inducements material to each employee entering into
employment with the Company. The options were granted in accordance
with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $4.40 per share,
which is equal to the closing price of the Company’s common stock
on the grant date. The options vest as to 25% of the total amount
of the award on the one-year anniversary of the grant date and in
thirty-six substantially equal monthly installments thereafter,
subject to the new employee’s continued service with the company.
Each stock option has a 10-year term. The options are subject to
the terms and conditions of LENSAR’s 2024 Employment Inducement
Incentive Award Plan and a stock option agreement covering the
grant.
About LENSAR
LENSAR is a commercial-stage medical device company focused on
designing, developing, and marketing advanced systems for the
treatment of cataracts and the management of astigmatism as an
integral aspect of the cataract procedure. LENSAR has developed its
next-generation ALLY® Adaptive Cataract Treatment System, the first
platform to integrate proprietary imaging and software, with an
extremely fast dual-pulse femtosecond laser in a compact, highly
ergonomic system. ALLY is designed to transform premium cataract
surgery by utilizing LENSAR’s advanced technologies with the
ability to perform the entire procedure in an operating room or
in-office surgical suite, delivering operational efficiencies and
reduced overhead. ALLY includes LENSAR’s proprietary Streamline®
software technology, designed to guide surgeons to achieve better
outcomes.
Contacts: |
|
Lee Roth / Cameron Radinovic |
Thomas R. Staab, II, CFO |
|
Burns McClellan for LENSAR |
ir.contact@lensar.com |
|
lroth@burnsmc.com / cradinovic@burnsmc.com |
LENSAR (NASDAQ:LNSR)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
LENSAR (NASDAQ:LNSR)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025